1407 The European Strategic Plan for children and adolescents with cancer

S200 while 2 cases died before evaluation. Three patients had experienced different management-related ophthalmic sequelae. Only one patient died due to chemotherapy-associated toxicity. The 4-years OS and 4-years FFS were 94.1±5.7% and 65.4±1.5% respectively. Conclusion: The current study demonstrated that RMS cases that present with orbit involvement are associated with better clinical outcome. Future treatment of patients with non-metastatic orbital RMS will focus on adjustments in therapy to reduce acute and late adverse effects while maintaining their excellent treatment outcome. New therapeutic approaches are required for the patients whose present outcome is less than optimal. No conflict of interest. 1407 POSTER The European Strategic Plan for children and adolescents with cancer G. Vassal1,18 , M. Schrappe2,18 , K. Pritchard-Jones3,18 , F. Arnold4 , L. Basset5 , A. Biondi6 , G. Bode7 , A. Eggert8 , L. Hjorth9 , L. Kameri´c10 , S. Karner7 , P. Kearns11 , A. Kienesberger7 , J. Kowalczyk12 , P. Lack13 , G. Perilongo14 , R. Sullivan15 , A. Tsirou16 , N. Kameri´c10 , S. Essiaf10 , R. Ladenstein17,18 . 1 Institut Gustave Roussy, Paris-Sud University, Division of Clinical Research, Paris, France; 2 Christian-Albrechts-University of Kiel, University Medical Centre Schleswig-Holstein, Department of Paediatrics, Kiel, Germany; 3 University College London, Institute of Child Health, Cancer Section, London, United Kingdom; 4 Union Nationale des Associations de Parents d’Enfants atteints de Cancer ´ ou Leucemie UNAPECLE-, UNAPECLE Office, Montpellier, France; 5 ˜ ˜ ´ Federacion Espanola de Padres de Ninos con Cancer FEPNC, FEPNC Office, Madrid, Spain; 6 Milano-Bicocca University, MBBM Foundation, San Gerardo Hospital, Paediatric Haematology-Oncology Department and “Tettamanti” Research Centre, Monza, Italy; 7 Childhood Cancer International CCI, Childhood Cancer International CCI − ¨ Europe, Nieuwegein, Netherlands; 8 Charite´ − Universitatsmedizin Berlin, Department of Paediatrics, Division of Oncology and Haematology, Berlin, 9 ˚ Germany; Skane University Hospital, Clinical Sciences, Lund University, Department of Paediatrics, Lund, Sweden; 10 The heart for the kids with cancer in FBiH/Cancer Survivor Network, The heart for the kids with cancer in FBiH/Cancer Survivor Network, Sarajevo, Bosnia-Herzegovina; 11 School of Cancer Sciences, University of Birmingham, Cancer Research UK Clinical Trials Unit CRCTU, Birmingham, United Kingdom; 12 Medical University Lublin, Department of Paediatric Haematology, Oncology and Transplantology, Lublin, Poland; 13 Childhood Cancer Switzerland, Childhood Cancer Switzerland, Basel, Switzerland; 14 University Hospital of Padua, University Hospital of Padua, Padua, Italy; 15 King’s College London, Division of Cancer Studies, Faculty Member, London, United Kingdom; 16 Kyttaro/Greek Survivors Association, Kyttaro/Greek Survivors Association, Athens, Greece; 17 Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung e.V., Vienna, Austria; 18 The European Society for Paediatric Oncology SIOPE, SIOPE Office, Brussels, Belgium Background: With 35,000 new cases every year, childhood cancer is an urgent public health issue in Europe. Access to standard care is unequally available across the continent. Survivors experience long-term effects, and, in spite of the improvements achieved, cancer remains the leading cause of disease-related death for children beyond one year of age. This is why the European paediatric haemato-oncology community joined forces to define a long term sustainable strategy to increase both the rate and the quality of cure in children and adolescents with cancer over the next decade. Material and Methods: As part of the FP7 ‘European Network for Cancer research in Children and Adolescents’ (ENCCA) project, a strategy was defined along with the Clinical Research Council (composed of all the European Clinical Trial groups and national societies in paediatric haematology oncology) and with parents and survivors from the Childhood Cancer International European group. Results: Seven medical and scientific objectives have been set up: i) Introducing safe and effective innovative treatments into multidisciplinary standard care; ii) Driving therapeutic decision by improved risk classification, the use of molecular characteristics and precision medicine; iii) Increasing knowledge of tumour biology and speeding up translation to benefit patients; iv) Increasing equal access across Europe to standard care, expertise and clinical research; v) Addressing the specific needs of teenagers and young adults, jointly with adult oncology; vi) Addressing the quality of survivorship; vii) Understanding the causes of paediatric cancers and addressing prevention where possible. The strategy achieved a broad consensus between all involved stakeholders. The European Society of Paediatric Oncology (SIOPE) is steering the effective implementation through dedicated programmes and cross tumour platforms, and will facilitate funding through European and national grants as well as from charities and industry.

Abstracts Conclusion: This European Childhood Cancer Plan is the outcome of a close partnership among all involved stakeholders. No conflict of interest. 1408 POSTER Evaluation of change in taste of children and adolescents with cancer during chemotherapy treatment E.B. Behling1 , B. Contini2 , L.B. Da Cruz3 . 1 University Federal of Rio Grande do Sul UFRGS, Departament of Nutrition, Porto Alegre, Brazil; 2 University Federal of Rio Grande do Sul UFRGS, Center for Studies in Food and Nutrition CESAN, Porto Alegre, Brazil; 3 Hospital de Cl´ınicas de Porto Alegre HCPA, Center for Studies in Food and Nutrition CESAN, Porto Alegre, Brazil Background: Chemotherapy provides important changes in taste. This taste changes contribute significantly to weight loss and malnutrition, since patients undergoing chemotherapy tend to develop food aversions and, consequently, consumption constraints. As result, it may compromise the nutritional status of there. The objective of this study was to evaluate changes of taste in children and adolescents with cancer during chemotherapy treatment. Material and Methods: This is a case-control cross-sectional study. We used the threshold detection test for evaluation of sweet and salty tastes. In total five different concentrations were used for each taste, that were offered in ascending order of concentration. The detection threshold corresponds to the solution in which the child detected a difference in taste between the glass of water and the glass the solute. Statistical analysis was performed using SPSS 18.0 software (SPSS Inc., USA). Results: The sample consisted of 48 individuals (24 patients with cancer and 24 healthy individuals). The average age of the sample was 12.3±3.4 years. 43.4% of the cases the threshold to detect the sweet taste offered to the third solution, while for control, this percentage was 62.5%. However, no significant difference was found for detection of taste between the groups (P = 0.218). Patients with cancer undergoing chemotherapy were less sensitive to salty taste than the controls (P < 0.001). According to the results, 83% of individuals in the control group detected this taste until the second concentration, whereas only 45.8% of patients with cancer detected by taste concentration. Conclusions: Patients with cancer undergoing chemotherapy are less sensitive to the perception of salty taste, thus requiring larger amounts of NaCl for detection of taste. Knowledge of the detection threshold becomes useful for guidance on the use of flavoring agents, combination of dietary ingredients and techniques capable of producing products and preparations more palatable, with the goal of greater acceptability feed children and adolescents with cancer. No conflict of interest. 1409 POSTER Temozolomide and valproic acid in combination with vinorelbine for treatment of pediatric high-grade gliomas: A preliminary analysis of a study protocol M. Lucchesi1 , A. Stival1 , L. Facchini1 , S. Becciani1 , A.M. Buccoliero2 , M. Guidi1 , S. Scoccianti3 , D. Greto3 , S. Farina1 , L. Genitori4 , I. Sardi1 . 1 Anna Meyer Children’s Hospital, Neuro-Oncology Unit − Department of Paediatric Medicine, Florence, Italy; 2 Anna Meyer Children’s Hospital, Pathology Unit, Florence, Italy; 3 Careggi University Hospital, Radiotherapy Unit, Florence, Italy; 4 Anna Meyer Children’s Hospital, Neurosurgery Unit − Department of Neuroscience, Florence, Italy Background: The prognosis for children with high-grade gliomas (HGGs: anaplastic astrocytoma, AA; glioblastoma multiforme, GBM) remains poor despite aggressive surgical resection and radiotherapy with concomitant and adjuvant temozolomide. Material and Methods: Our proposal for pediatric HGGs was a chemoradiotherapy protocol developed by EORTC/NCIC for adults (Neurology, 2011), with Vinorelbine (20 mg/sqm iv weekly during radiotherapy, and 30 mg/sqm iv bi-weekly in the adjuvant phase). Moreover, the adjuvant phase was prolonged to 12 months. Results: We treated 15 pediatric patients. Twelve (80%) have completed treatment at the time of analysis. The median age was 10 years (range 6−24). Five (33%) patients had a GBM, and 10 (67%) had an AA. We have considered 12 (80%) supratentorial (5, 42% in hemispheres and 7, 58% in diencephalon) and 3 (20%) infratentorial (2, 67% in brainstem and 1, 33% in cerebellum) tumors. Surgery was performed in 13 (86,7%) patients. It was radical without residual in 5 (38,4%) cases. Six patients (40%) had a disease progression during the adjuvant phase. About these patients, five (84%) have received a second line treatment (Gemcitabine